Steven Sklar v. Amarin Corp. PLC; Joseph Zakrzewski

     Amarin misrepresented the Food and Drug Administration’s intent to approve its product, Vascepa, and the CEO dumped $11 million of his own shares at the inflated prices, a class claims.